Table 2 Quantification of the intravenous treatment effects.
From: Non-carbohydrate anaplerotic therapy counters empagliflozin-induced diabetic ketosis
Treatments | P-Values | |||||
|---|---|---|---|---|---|---|
Blood Parameters | Glycerol (Mean ± SE) | Saline (Mean ± SE) | SEM | Treatment | Sequence | Treatment X Sequence |
Experiment 1: IV GLY VS. SAL | ||||||
Delta BHB, % | −28.5 ± 4.5 | −11.5 ± 8.6 | 5.7 | 0.03 | 0.6 | 0.02 |
AUC BHB, h x mM | −1.6 ± 0.7 | 2.5 ± 0.6 | 0.8 | 0.006 | 0.8 | 0.2 |
Delta Glucose, % | 63.3 ± 13.2 | 10.5 ± 21.2 | 14.8 | 0.04 | 0.2 | 0.8 |
AUC Glucose, h x mg/dL | 279.0 ± 38.7 | −122.0 ± 82.7 | 106.3 | 0.01 | 0.1 | 0.8 |
Experiment 2: IV Insulin-GLY VS. Insulin-SAL | ||||||
Delta BHB, % | −48.1 ± 8.1 | −23.8 ± 7.8 | 6.7 | 0.001 | 0.8 | 0.4 |
AUC BHB, h x mM | −4.50 ± 1.7 | −1.7 ± 1.3 | 1.1 | 0.03 | 1.0 | 0.9 |
Delta Glucose, % | −21.4 ± 3.2 | −30.9 ± 5.5 | 3.5 | 0.05 | 0.5 | 0.09 |
AUC Glucose, h x mg/dL | −51.5 ± 20.6 | −155.2 ± 15.7 | 22.1 | 0.004 | 0.9 | 0.08 |
Delta NEFA, % | −66.6 ± 3.2 | −60.07 ± 5.6 | 3.3 | 0.14 | 0.1 | 0.3 |
AUC NEFA, h x mEq/L | −0.7 ± 0.1 | −0.3 ± 0.3 | 0.2 | 0.3 | 0.3 | 0.7 |
